Paolo Ambrosino Selected Research

Paolo Ambrosino Research Topics

Disease

9	Brain Diseases (Brain Disorder) 11/2023 - 03/2013
9	Epilepsy (Aura) 01/2022 - 06/2009
4	Seizures (Absence Seizure) 01/2024 - 03/2009
4	Pain (Aches) 09/2019 - 03/2013
2	COVID-19 01/2023 - 01/2022
2	Hyperalgesia 07/2018 - 11/2013
2	Benign Neonatal Epilepsy (Benign Familial Neonatal Convulsions) 03/2014 - 01/2011
1	Partial Epilepsies (Epilepsy, Partial) 01/2024
1	Myoclonic Epilepsies (Myoclonic Encephalopathy) 01/2023
1	Ataxia (Dyssynergia) 01/2023
1	Infections 01/2023
1	Rare Diseases (Rare Disease) 07/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022
1	Neoplasms (Cancer) 12/2020
1	Prostatic Neoplasms (Prostate Cancer) 12/2020
1	Neuralgia (Stump Neuralgia) 07/2017
1	Pathologic Processes 07/2017
1	Hypoxia (Hypoxemia) 05/2016
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 08/2015
1	Infarction (Infarctions) 08/2015
1	Brain Ischemia (Cerebral Ischemia) 08/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2014
1	Stroke (Strokes) 01/2013
1	Convulsions benign familial neonatal dominant form 06/2009

Drug/Important Bio-Agent (IBA)

8	Potassium Channels (Potassium Channel)IBA 11/2023 - 01/2010
3	Anticonvulsants (Antiepileptic Drugs)IBA 03/2013 - 01/2010
2	Fluoxetine (Prozac)FDA LinkGeneric 01/2024 - 01/2023
2	CalciumIBA 12/2020 - 03/2013
2	PotassiumIBA 10/2020 - 06/2009
2	BradykininIBA 09/2019 - 03/2013
2	Capsaicin (Zostrix)FDA Link 09/2019 - 03/2013
2	Phosphatidylinositols (Phosphatidylinositol)IBA 08/2018 - 12/2016
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2018 - 07/2017
2	ezogabine (retigabine)IBA 05/2016 - 01/2010
1	Antidepressive Agents (Antidepressants)IBA 01/2024
1	Indicators and Reagents (Reagents)IBA 01/2023
1	Particulate MatterIBA 01/2023
1	Calcium Carbonate (Limestone)FDA Link 07/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Immunoglobulin M (IgM)IBA 01/2022
1	AntibodiesIBA 01/2022
1	KCNQ2 Potassium ChannelIBA 01/2022
1	CationsIBA 12/2020
1	Transient Receptor Potential ChannelsIBA 12/2020
1	Gabapentin (Neurontin)FDA LinkGeneric 10/2020
1	Quinidine (Chinidin)FDA LinkGeneric 10/2018
1	icilinIBA 07/2018
1	Tryptophan (L-Tryptophan)FDA Link 07/2018
1	allyl isocyanateIBA 07/2017
1	allyl isothiocyanateIBA 07/2017
1	Hydrogen Sulfide (Sulfide, Hydrogen)IBA 07/2017
1	isothiocyanic acidIBA 07/2017
1	sodium bisulfide (NaHS)IBA 07/2017
1	GasotransmittersIBA 07/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 07/2017
1	IsothiocyanatesIBA 07/2017
1	Hemoglobins (Hemoglobin)IBA 07/2017
1	Calmodulin (Calcium-Dependent Activator Protein)IBA 09/2015
1	5- amino- N- butyl- 2- (4- ethoxyphenoxy)- benzamide hydrochlorideIBA 08/2015
1	Glucose (Dextrose)FDA LinkGeneric 08/2015
1	Oxygen (Dioxygen)IBA 08/2015
1	Sodium-Calcium ExchangerIBA 08/2015
1	Protein Isoforms (Isoforms)IBA 08/2015
1	Dihydrotachysterol (AT 10)IBA 08/2015
1	KCNQ3 Potassium ChannelIBA 03/2015
1	LeptinIBA 09/2014
1	Large-Conductance Calcium-Activated Potassium Channels (Maxi-K Channels)IBA 09/2014
1	N-Methylaspartate (NMDA)IBA 09/2014
1	Syntaxin 1IBA 03/2014
1	IsoxazolesIBA 11/2013
1	AntiportersIBA 01/2013
1	7- nitro- 5- phenyl- 1- (pyrrolidin- 1- ylmethyl)- 1H- benzo(e)(1,4)diazepin- 2(3H)- oneIBA 01/2013
1	Neuroprotective AgentsIBA 01/2013

Therapy/Procedure

5	Therapeutics 12/2020 - 01/2010
1	Precision Medicine 01/2023
1	Critical Care (Surgical Intensive Care) 01/2022
1	Drug Therapy (Chemotherapy) 07/2017
1	Intraperitoneal Injections 03/2009